Post-earnings recap
Reported
Mon, Aug 10, 2026
EPS actual
$-1.52
EPS est.
$-1.60
EPS surprise
+5.12%
1-day move
-3.98%
Vera Therapeutics reported a smaller loss per share than analysts expected, which is a positive sign. However, the stock fell by nearly 4% in reaction to the overall lack of revenue and guidance. Investors may be cautious as the company did not provide any updates or insights during the earnings call.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.52 | $-1.59 | +5.12% |
| Revenue | $0M | $0M | — |
No transcript is on record, and the analysis is based solely on numerical results.
Vera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious autoimmune diseases. Operating in the health care sector, Vera's work is crucial as it addresses unmet medical needs and aims to improve patient outcomes through advanced treatments.
Last quarter
In Q1-2026, Vera reported an EPS of -1.69, missing estimates by a significant margin. The stock reacted negatively, dropping 1.95% the following day.
EPS beat streak
1Q
EPS beat rate
13%
Avg EPS surprise
-45.42%
Avg 1-day reaction
-1.92%
Analysts expect continued losses this quarter, with a consensus EPS of -1.59. Investors are looking for any signs of progress in product development or potential revenue streams.
Bull case
If Vera can demonstrate advancements in their drug pipeline or provide positive updates on clinical trials, it could boost investor confidence and lead to a positive stock reaction.
Bear case
Conversely, if Vera fails to meet EPS expectations again or provides no clarity on future revenue, it may lead to further declines in stock price.
Key metrics to watch
EPS
-1.59Earnings per share is a key indicator of the company's profitability and financial health, especially as they continue to develop their therapies.
Revenue
0MWhile no revenue is expected this quarter, any updates on future revenue potential from product development will be closely watched.
The print will turn on these.
Q1
Will Vera provide any updates on the progress of their drug pipeline?
Investors are keen to understand if there are any advancements that could lead to future revenue, especially given the lack of expected revenue this quarter.
Q2
How does management plan to address the ongoing losses?
Understanding management's strategy for mitigating losses will be crucial for investor confidence and could impact stock performance.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±18.2%
Why consensus could be wrong
The consensus may underestimate the potential for positive news from ongoing trials, which could lead to unexpected revenue opportunities.
Supporting evidence
The high implied move from options suggests that the market is bracing for significant news, indicating potential upside.
Vera's historical performance shows that even amidst losses, there have been instances of positive stock reactions based on trial updates.
Key risk
If there are any unexpected positive developments in their drug pipeline, it could significantly shift market sentiment.
Pre-commit to what would confirm each case.
The market is weighing the potential for future revenue against ongoing losses, making this a pivotal quarter for Vera.
Bull confirmed if
Positive updates on drug development or a narrower EPS loss than expected could confirm the bull case.
Bear confirmed if
A wider EPS loss or no clarity on future revenue would confirm the bear case.
What the market is pricing for the move.
Implied Move
±41.6%
Historical Avg
±3.3%
The options market is pricing in a significant potential move, indicating high uncertainty around the earnings report.
Options are pricing ±41.6% while VERA has averaged ±3.3% over the last 8 prints — setup is pricing rich.
ATM IV
1.0%
30d HV
50.5%
Smart-money positioning from the most recent 13F filings.
Institutional
118.09%
of float
Insider
0.95%
of float
Holders
311
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
5,747,760 sh · $173.9M
7.98%
13.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Vera beats EPS expectations and provides positive updates, history suggests the stock could rise significantly, potentially around 3.5%.
In line / cautious
If results are in line but management is cautious, the stock may experience a muted reaction as investors await further clarity.
Miss
A miss on EPS could lead to a decline, with history suggesting an average drop of around 2.15% following such outcomes.
The lines on the call that would change the story.
Avoro Capital Advisors LLC
5,723,888 sh · $173.1M
7.94%
-2.8%
State Street Corporation
4,148,786 sh · $125.5M
5.76%
23.3%
Price (T.Rowe) Associates Inc
4,012,936 sh · $121.4M
5.57%
-12.3%
Deep Track Capital, Lp
4,000,000 sh · $121.0M
5.55%
-2.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.